RET and non-small cell lung carcinoma: In a recent 2020 paper, Lin and coworkers assessed 20 tissue and/or cfDNA biopsies from 18 RET+ advanced NSCLC patients after RET-selective TKI treatment (10 patients received selpercatinib, seven patients received pralsetinib, and one patient received pralsetinib and selpercatinib).